ArticleCureus2025
Macrophage Activation Syndrome in Adult-Onset Still's Disease: Challenges in Early Detection and Management.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Adult-Onset Still's Disease in a Patient with Macrophage Activation Syndrome and Pre-Disseminated Intravascular Coagulation: A Case Report and Literature Review.Journal of inflammation research · 2026Article
- Advancing Precision Medicine in Adult-Onset Still's Disease: Insights into Biomarkers, Therapies, and COVID-19 Impacts.Mediterranean journal of rheumatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult-onset Still's disease (AOSD) is an immunological disorder that manifests with fever, evanescent rash, leukocytosis, and arthralgia. One of the most severe complications of AOSD is macrophage activation syndrome, a life-threatening complication characterized by hyperactivation of the immune system and multiorgan dysfunction. This case report describes a 24-year-old female who developed macrophage activation syndrome in the setting of AOSD. Initially, she developed heterogeneous and nonspecific symptoms of fever, pharyngitis, rash, lymphadenopathy, and migratory arthralgia after a trip to Mexico. Thus, the diagnosis and appropriate treatment were delayed. Although her symptoms were temporarily relieved with oral steroids, she worsened clinically. She developed a widespread rash, persistent fever, a very high ferritin level (29,972 ng/mL), and elevated liver enzymes with mild hepatosplenomegaly, raising concern for macrophage activation syndrome. After ruling out infections, she was diagnosed with AOSD, and treatment with intravenous steroids was started, resulting in clinical improvement. Macrophage activation syndrome is a rare but fatal complication. Early recognition, particularly with elevated ferritin, liver dysfunction, and thrombocytopenia, is very important. Early intervention with glucocorticoids and biologics like anakinra is crucial for improving outcomes. The patient is in remission with ongoing follow-up with rheumatology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.